Serum Neuroinflammatory Markers' Levels and Evaluation of Peripheral Large Nerve Fibre Function in Patients with Psoriasis

Basit Öğe Kaydı
dc.contributor.authorBalevi, Ali
dc.contributor.authorOzdemir, Mustafa
dc.contributor.authorGuney, Figen
dc.contributor.authorTol, Huseyin
dc.contributor.authorOkudan, Nilsel
dc.contributor.authorBelviranli, Muaz
dc.contributor.authorSahin, Kemal Tahir
dc.date.accessioned2020-03-26T19:26:18Z
dc.date.available2020-03-26T19:26:18Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: Currently, tumor necrosis factor-alpha (TNF-alpha) inhibitors are widely used all over the world, especially in the treatment of severe psoriasis. However, multiple sclerosis (MS) and peripheral neuropathy occurrence associated with TNF-a inhibitors have been reported in the treatment of patients with psoriasis. It is not known whether TNF-a inhibitors reveal underlying neurological disorders in patients with psoriasis. The aim of this study was to investigate whether there is an association between psoriasis and MS or peripheral neuropathy. Methods: In this study, 50 psoriasis patients and 25 healthy controls were enrolled. Neurological examination and needle electromyography test were performed. Serum levels of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), S-100 calcium-binding protein (S100B) and neuron specific enolase (NSE), which are involved in neuroinflammatory process, were measured. Results: Serum MMP-9 levels were higher in psoriasis patients compared to healthy controls. Serum MMP-2 and NSE levels were decreased in psoriasis patients compared to healthy controls. There was no significant difference in S100B levels between two groups. All neurophysiological parameters in each individual patient and control were found to be within normal limits and there was no difference between groups. Conclusion: NSE and MMP-9 might play role in the occurrence of MS in psoriasis patients. Especially, we are in the opinion that it might be useful to measure the serum levels of these markers before the administration of TNF-a inhibitors in psoriasis patients with family history of MS.en_US
dc.identifier.doi10.4274/tdd.2835en_US
dc.identifier.endpage58en_US
dc.identifier.issn1307-7635en_US
dc.identifier.issn1308-5255en_US
dc.identifier.issue2en_US
dc.identifier.pmid#YOKen_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage54en_US
dc.identifier.urihttps://dx.doi.org/10.4274/tdd.2835
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33984
dc.identifier.volume10en_US
dc.identifier.wosWOS:000377870400003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherGALENOS YAYINCILIKen_US
dc.relation.ispartofTURK DERMATOLOJI DERGISI-TURKISH JOURNAL OF DERMATOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectPsoriasisen_US
dc.subjectmatrix metalloproteinase 2en_US
dc.subjectmatrix metalloproteinase 9en_US
dc.subjectS-100 calcium-binding protein beta subuniten_US
dc.subjectneuron specific enolaseen_US
dc.subjectelectromyographyen_US
dc.titleSerum Neuroinflammatory Markers' Levels and Evaluation of Peripheral Large Nerve Fibre Function in Patients with Psoriasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu